Imipramine Is an Orally Active Drug against Both Antimony Sensitive and Resistant Leishmania donovani Clinical Isolates in Experimental Infection

PLoS Neglected Tropical Diseases

Volumn 6, Issue 12, 2012, Pages

  Mukherjee, Sandip ^a   Mukherjee, Budhaditya ^a   Mukhopadhyay, Rupkatha ^a   Naskar, Kshudiram ^a   Sundar, Shyam ^b   Dujardin, Jean Claude ^c   Das, Anjan Kumar ^d   Roy, Syamal ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b BANARAS HINDU UNIVERSITY   (India)

^c INSTITUTE OF TROPICAL MEDICINE   (Belgium)

^d CALCUTTA NATIONAL MEDICAL COLLEGE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMONY; GAMMA INTERFERON; IMIPRAMINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; MILTEFOSINE; REACTIVE OXYGEN METABOLITE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

AMASTIGOTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANISOTROPY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBODY RESPONSE; ANTIGEN PRESENTATION; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; FLOW CYTOMETRY; HAMSTER; HISTOLOGY; LEISHMANIA DONOVANI; LEISHMANIASIS; LIVER GRANULOMA; MACROPHAGE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PARASITE CLEARANCE; PERITONEAL EXUDATE CELL; PROMASTIGOTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADMINISTRATION, ORAL; ANIMALS; ANTIMONY; ANTIPROTOZOAL AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE; IMIPRAMINE; LEISHMANIA DONOVANI; LEISHMANIASIS, VISCERAL; PARASITIC SENSITIVITY TESTS; TREATMENT OUTCOME;

EID: 84872032614     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0001987     Document Type: Article

References (70)

1. Clem A, (2010) A current perspective on leishmaniasis. J Glob Infect Dis 2: 124-126.
2. Sundar S, More DK, Singh MK, Singh VP, Sharma S, et al. (2000) Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis 31: 1104-1107.
3. Sundar S, (2001) Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health 6: 849-854.
4. Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, et al. (2000) Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 18: 2476-2483.
5. Pandey BD, Pandey K, Kaneko O, Yanangi T, Hirayama K, (2009) Short Report: Relapse of Visceral Leishmaniasis after Miltefosine Treatment in Nepalese Patient. Am J Trop Med Hyg 80: 580-582.
6. Srivastava P, Prajapati VK, Rai M, Sundar S, (2011) Unusual case of resistance to amphotericin B in visceral leishmaniasis in a region in India where leishmaniasis is not endemic. J Clin Microbiol 49: 3088-3091.
7. Esperanca M, Gerrard JW, (1969) Nocturnal enuresis: comparison of the effect of imipramine and dietary restriction on bladder capacity. Can Med Assoc J 101: 65-68.
8. Peghini PL, Katz PO, Castell DO, (1998) Imipramine decreases oesophageal pain perception in human male volunteers. Gut 42: 807-813.
9. Gilman AG (1990) Goodman & Gilman's The Pharmacological Basis of Therapeutics. Peragmon Press. pp. 383-435.
10. Zilberstein D, Liveanu V, Gepstein A, (1990) Tricyclic drugs reduce proton motive force in Leishmania donovani promastigotes. Biochem Pharmacol 39: 935-940.
11. Benson TJ, McKie JH, Garforth J, Borges A, Fairlamb AH, et al. (1992) Rationally designed selective inhibitors of trypanothione reductase. Phenothiazines and related tricyclics as lead structures. Biochem J 286 (Pt 1) (): 9-11.
12. Kubera M, Kenis G, Bosmans E, Kajta M, Basta-Kaim A, et al. (2004) Stimulatory effect of antidepressants on the production of IL-6. Int Immunopharmacol 4: 185-192.
13. Halliwell WH, (1997) Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 25: 53-60.
14. Evans AT, Croft SL, (1994) Antileishmanial actions of tricyclic neuroleptics appear to lack structural specificity. Biochem Pharmacol 48: 613-616.
15. Mukhopadhyay R, Mukherjee S, Mukherjee B, Naskar K, Mondal D, et al. (2011) Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol 41: 1311-1321.
16. Sen S, Roy K, Mukherjee S, Mukhopadhyay R, Roy S, (2011) Restoration of IFNgammaR subunit assembly, IFNgamma signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterol. PLoS Pathog 7: e1002229.
17. Verma NK, Dey CS, (2004) Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob Agents Chemother 48: 3010-3015.
18. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.
19. Kremb S, Helfer M, Heller W, Hoffmann D, Wolff H, et al. (2010) EASY-HIT: HIV full-replication technology for broad discovery of multiple classes of HIV inhibitors. Antimicrob Agents Chemother 54: 5257-5268.
20. da Luz RI, Vermeersch M, Dujardin JC, Cos P, Maes L, (2009) In vitro sensitivity testing of Leishmania clinical field isolates: preconditioning of promastigotes enhances infectivity for macrophage host cells. Antimicrob Agents Chemother 53: 5197-5203.
21. Reers M, Smith TW, Chen LB, (1991) J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry 30: 4480-4486.
22. Paris C, Loiseau PM, Bories C, Breard J, (2004) Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob Agents Chemother 48: 852-859.
23. Shinitzky M, Inbar M, (1974) Difference in microviscosity induced by different cholesterol levels in the surface membrane lipid layer of normal lymphocytes and malignant lymphoma cells. J Mol Biol 85: 603-615.
24. Mukherjee SB, Das M, Sudhandiran G, Shaha C, (2002) Increase in cytosolic Ca2+ levels through the activation of non-selective cation channels induced by oxidative stress causes mitochondrial depolarization leading to apoptosis-like death in Leishmania donovani promastigotes. J Biol Chem 277: 24717-24727.
25. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, et al. (1982) Analysis of nitrate, nitrite, and [15N]nitrate in biological fluids. Anal Biochem 126: 131-138.
26. McNeely TB, Doyle PS, (1996) Isolation of lipophosphoglycans from Leishmania donovani amastigotes. Arch Biochem Biophys 334: 1-8.
27. Basu R, Bhaumik S, Basu JM, Naskar K, De T, et al. (2005) Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and-resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generation: evidence for mixed Th1- and Th2-like responses in visceral leishmaniasis. J Immunol 174: 7160-7171.
28. Benkert O, Grunder G, Wetzel H, Hackett D, (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30: 441-451.
29. Reagan-Shaw S, Nihal M, Ahmad N, (2008) Dose translation from animal to human studies revisited. FASEB J 22: 659-661.
30. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, et al. (1990) Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microspheres target the Peyer's patches. J Contr Rel 11: 205-214.
31. Melby PC, Chandrasekar B, Zhao W, Coe JE, (2001) The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response. J Immunol 166: 1912-1920.
32. Banerjee S, Ghosh J, Sen S, Guha R, Dhar R, et al. (2009) Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells. Infect Immun 77: 2330-2342.
33. Zilberstein D, Dwyer DM, (1984) Antidepressants cause lethal disruption of membrane function in the human protozoan parasite Leishmania. Science 226: 977-979.
34. Mookerjee Basu J, Mookerjee A, Sen P, Bhaumik S, Banerjee S, et al. (2006) Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob Agents Chemother 50: 1788-1797.
35. Gottlieb E, Armour SM, Harris MH, Thompson CB, (2003) Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ 10: 709-717.
36. Ly JD, Grubb DR, Lawen A, (2003) The mitochondrial membrane potential (deltapsi(m)) in apoptosis; an update. Apoptosis 8: 115-128.
37. Chakraborty D, Banerjee S, Sen A, Banerjee KK, Das P, et al. (2005) Leishmania donovani affects antigen presentation of macrophage by disrupting lipid rafts. J Immunol 175: 3214-3224.
38. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, et al. (2002) Molecular Biology of The Cell. Garland Science. pp 583-614.
39. Adams CM, Goldstein JL, Brown MS, (2003) Cholesterol-induced conformational change in SCAP enhanced by Insig proteins and mimicked by cationic amphiphiles. Proc Natl Acad Sci U S A 100: 10647-10652.
40. Sundar S, Olliaro PL, (2007) Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag 3: 733-740.
41. Rybczynska M, Liu R, Lu P, Sharom FJ, Steinfels E, et al. (2001) MDR1 causes resistance to the antitumour drug miltefosine. Br J Cancer 84: 1405-1411.
42. Chatelain E, Ioset JR, (2011) Drug discovery and development for neglected diseases: the DNDi model. Drug Des Devel Ther 5: 175-181.
43. Sundar S, Sinha PK, Rai M, Verma DK, Nawin K, et al. (2011) Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial. Lancet 377: 477-486.
44. Basu R, Roy S, Walden P, (2007) HLA class I-restricted T cell epitopes of the kinetoplastid membrane protein-11 presented by Leishmania donovani-infected human macrophages. J Infect Dis 195: 1373-1380.
45. Liew FY, Wei XQ, Proudfoot L, (1997) Cytokines and nitric oxide as effector molecules against parasitic infections. Philos Trans R Soc Lond B Biol Sci 352: 1311-1315.
46. Anderson CF, Lira R, Kamhawi S, Belkaid Y, Wynn TA, et al. (2008) IL-10 and TGF-beta control the establishment of persistent and transmissible infections produced by Leishmania tropica in C57BL/6 mice. J Immunol 180: 4090-4097.
47. Barral-Netto M, Barral A, Brownell CE, Skeiky YA, Ellingsworth LR, et al. (1992) Transforming growth factor-beta in leishmanial infection: a parasite escape mechanism. Science 257: 545-548.
48. Ghalib HW, Piuvezam MR, Skeiky YA, Siddig M, Hashim FA, et al. (1993) Interleukin 10 production correlates with pathology in human Leishmania donovani infections. J Clin Invest 92: 324-329.
49. Li J, Hunter CA, Farrell JP, (1999) Anti-TGF-beta treatment promotes rapid healing of Leishmania major infection in mice by enhancing in vivo nitric oxide production. J Immunol 162: 974-979.
50. Murphy ML, Wille U, Villegas EN, Hunter CA, Farrell JP, (2001) IL-10 mediates susceptibility to Leishmania donovani infection. Eur J Immunol 31: 2848-2856.
51. Padigel UM, Alexander J, Farrell JP, (2003) The role of interleukin-10 in susceptibility of BALB/c mice to infection with Leishmania mexicana and Leishmania amazonensis. J Immunol 171: 3705-3710.
52. Ranatunga D, Hedrich CM, Wang F, McVicar DW, Nowak N, et al. (2009) A human IL10 BAC transgene reveals tissue-specific control of IL-10 expression and alters disease outcome. Proc Natl Acad Sci U S A 106: 17123-17128.
53. Saha S, Mondal S, Ravindran R, Bhowmick S, Modak D, et al. (2007) IL-10- and TGF-beta-mediated susceptibility in kala-azar and post-kala-azar dermal leishmaniasis: the significance of amphotericin B in the control of Leishmania donovani infection in India. J Immunol 179: 5592-5603.
54. Wilson ME, Young BM, Davidson BL, Mente KA, McGowan SE, (1998) The importance of TGF-beta in murine visceral leishmaniasis. J Immunol 161: 6148-6155.
55. Haldar AK, Yadav V, Singhal E, Bisht KK, Singh A, et al. (2010) Leishmania donovani isolates with antimony-resistant but not-sensitive phenotype inhibit sodium antimony gluconate-induced dendritic cell activation. PLoS Pathog 6: e1000907.
56. Tsunawaki S, Sporn M, Ding A, Nathan C, (1988) Deactivation of macrophages by transforming growth factor-beta. Nature 334: 260-262.
57. Bogdan C, Vodovotz Y, Nathan C, (1991) Macrophage deactivation by interleukin 10. J Exp Med 174: 1549-1555.
58. Lee YJ, Han Y, Lu HT, Nguyen V, Qin H, et al. (1997) TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression. J Immunol 158: 2065-2075.
59. Stanley AC, Engwerda CR, (2007) Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 85: 138-147.
60. Smelt SC, Cotterell SEJ, Engwerda CR, Kaye PM, (2000) B cell-deficient mice are highly resistant to Leishmania donovani infection, but develop neutrophil-mediated tissue pathology. The Journal of Immunology 164: 3681.
61. Stäger S, Alexander J, Carter KC, Brombacher F, Kaye PM, (2003) Both interleukin-4 (IL-4) and IL-4 receptor α signaling contribute to the development of hepatic granulomas with optimal antileishmanial activity. Infection and immunity 71: 4804-4807.
62. Murray HW, (2001) Tissue granuloma structure-function in experimental visceral leishmaniasis. Int J Exp Pathol 82: 249-267.
63. Murray HW, Nathan CF, (1999) Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J Exp Med 189: 741-746.
64. Tumang M, Keogh C, Moldawer LL, Helfgott DC, Teitelbaum R, et al. (1994) Role and effect of TNF-alpha in experimental visceral leishmaniasis. The Journal of Immunology 153: 768-775.
65. Kaye PM, Svensson M, Ato M, Maroof A, Polley R, et al. (2004) The immunopathology of experimental visceral leishmaniasis. Immunol Rev 201: 239-253.
66. Carter KC, Henriquez FL, Campbell SA, Roberts CW, Nok A, et al. (2007) DNA vaccination against the parasite enzyme gamma-glutamylcysteine synthetase confers protection against Leishmania donovani infection. Vaccine 25: 4502-4509.
67. Mookerjee Basu J, Mookerjee A, Banerjee R, Saha M, Singh S, et al. (2008) Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother 52: 1080-1093.
68. Benkert O, Grunder G, Wetzel H, Hackett D, (1996) A randomized, double-blind comparison of a rapidly escalating dose of venlafaxine and imipramine in inpatients with major depression and melancholia. J Psychiatr Res 30: 441-451.
69. Szabo D, Szabo G Jr, Ocsovszki I, Aszalos A, Molnar J, (1999) Anti-psychotic drugs reverse multidrug resistance of tumor cell lines and human AML cells ex-vivo. Cancer Lett 139: 115-119.
70. Wibo M, Poole B, (1974) Protein degradation in cultured cells. II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol 63: 430-440.